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Correction of Thiazide Hyperuricemia by Potassium 
Chloride and Ammonium Chloride 
By ANDREW J. ZWEIFLER AND GEORGE R. THOMPSON 
Large doses of KCI lowered serum uric 
acid while producing mild, apparently 
unrelated, uricosuria in four chloro- 
thiazide-treated subjects. In two con- 
trol subjects KCI also caused mild 
uricosuria, but had a negligible effect 
on serum uric acid concentration. Am- 
monium chloride decreased serum urate 
in all six subjects, while urinary uric 
acid excretion remained essentially un- 
changed. It is suggested that these 
changes in serum uric acid are sec- 
ondary to redistribution of urate among 
body compartments. 
Grande doses de KCI reduceva le con- 
centrationes seral de acido uric e pro- 
duceva leve grados de apparentemente 
non relationate uricosuria in quatro sub- 
jectos sub tractamento a chlorothiazida. 
In duo subjectos de controlo, KCI cau- 
sava similemente leve grados de urico- 
suria sed exerceva non plus que un 
negligible effecto super le nivellos seral 
de acido uric. Chloruro de ammonium 
reduceva le urato seral in omne casos 
in un serie de 6 subjectos durante que 
le excretion urinari de acido uric re- 
maneva essentialmente inalterate. Es 
postulate que iste alterationes in le 
nivello seral de acido uric es un effecto 
secundari del redistribution de urato in 
le diverse compartimentos corporee. 
T HAS BEEN REPORTED1 and confirmed2 that large doses of potassium I chloride lower serum uric acid concentration in patients receiving thiazide 
diuretics, but the reason for this response has not been apparent. The results 
of the present investigations indicate that both KC1 and NH4C1 correct 
thiazide hyperuricemia and that the mechanism of this effect is primarily 
nonrenal. 
MATERIALS AND METHODS 
Six individuals were studied. Four had received chlorothiazide (1.0 to 2.0 Gm. per 
day) for at least one month. One of these was a female (L. A., 64 Kg.) with essential 
hypertension, impaired renal function (creatinine clearance 50 L./24 hr. ), and past 
cardiac decompensation. The other three (J. M., 65 Kg.; F. B., 66 Kg.; C. W., 60 Kg.) 
were normotensive, nonedematous males without azotemia. The other two subjects were 
male medical students who were given no chlorothiazide (R. S., 88 Kg.; M. W., 78 Kg.). 
Investigations on all four of the thiazide-treated individuals were carried out while they 
lived in the Clinical Research Unit of the University of Michigan Medical Center. Al- 
though the two medical students ate and slept in the Clinical Research Unit, they con- 
tinued functioning as clinical clerks on the University Hospitals wards during this time. 
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Serum upit acid (mp.$) 
Sub3ectS f i e -KC1 K C 1  Chaoge 
1135 
Urine uric acid (mpdZ4”) urate c1eanmce:creatinine Clearance 
(Expressed as per cent) 
P r e - K C l  K C 1  Char@ h - K C l  KC1 Ctmge 
L . A . t  6.% 4.85 -2 .U 
F.B.t 7.33 5.30 -2.03 
J.M.t 6.05 4.30 -1.75 
c.w.t 5.28 4.60 -0.68 
M.W. 5.55 5.50 -0.05 
R.S .  6.60 5.95 -0.65 
180 430 +250 6.50 12.9 6.40 
1260 1273 t l 3  7.40 8.66 t1.26 
350 463 +I13 5.70 7.80 t2.10 
425 653 e a  4.50 6.85 +2.35 
785 a57 +P 6.20 6.84 4 . 6 4  
633 a26 +I93 4.85 6.49 +1.64 
-411 subjects received a diet that was relatively constant in purine and provided at  
least 30 calories/Kg./day. The intakes of both sodium and potassium were maintained at 
90 mEq./day. Fluids were allowed as desired. 
Weight and blood pressure were recorded daily, and 24 hour urine collections were 
completed at 800 a.m. each day. Venous blood for uric acid, creatinine, and potassium 
determinations was obtained frequently, and additional blood for Na+, C1-, HCO,-, 
and pH was collected at the beginning and the end of each treatment period. The fol- 
lowing measurements were made on daily 24 hour urine specimens: volume; pH; uric 
acid; creatinine; Na+, K+, and C1- content. 
All subjects underwent at least two treatment periods, one in which they received KC1 
12.0 Gm./day, and another in which they took NH,CI 12.0 Gm./day. These salts were 
administered orally in the form of a syrup. The duration of the KC1 period was three 
to four days in the patients receiving chlorothiazide and seven days in the control 
subjects. NH,C1 was given for three to five days. All treatment periods were separated 
by at least four days. One subject (L .  A.) had additional treatment periods with potas- 
sium gluconate 160 mEq./day, spironolactone-A 200 mg./day, and NaCl 256 mEq./day 
(administered orally). 
Serum and urinary uric acid were determined by a modified colorimetric method.3 
Creatinine was determined utilizing the Jaffe reaction on a “Technicon” Auto-Analyzer. 
Serum and urinary sodium, potassium, and chloride were determined by emission spectro- 
photometry, using an E.E.L. flame photometer. Serum carbon dioxide combining power 
was measured with a Natelson microgasometer. Blood pH was determined from heparin- 
ized venous blood, using a Radiometer microglass electrode p H  meter. Urine p H  was 
determined with a Beckman pH meter.” 
RESULTS 
E8ec.t of KCl 
As can be seen in table 1, serum uric acid concentration fell substantially 
in three of four thiazide-treated patients, and slightly in the fourth, during 
“We wish to thank Dr. William Mikkelsen of the Rackham Arthritis Research Unit in 
whose laboratory the uric acid determinations were performed, and Dr. J. Chandler who 
supervised the performance of all of the other tests in the laboratories of the Clinical 
Research Unit, 
1136 
PATIENT F . B .  CHLOROTHIAZIDE IOOOmgJD 
ZWEIFLER AND THOMPSON 
SERUM URIC ACID 
mg. % 6.0 
5.0 
URINARY URIC ACID ‘Oo0 
mg.124’ 500 
0 








r - - 7 , -  7, I I , I 1 , 7 I / I I I I I  _ r l - 7  
2 5 8 II 14 28 31 3 4  37 4 0  
DAY DAY 
Fig. 1.-Daily variations in the serum uric acid, urine urate, urate clearance: 
creatinine clearance ratio, and urine volume, during control and treatment periods 
with NH,C1 and KC1. This patient (F. R.) had been taking chlorothiazide, 1.0 
Gm. per day, for over one month prior to, and during the study. Note the absence 
of significant uricosuria and the large drop of serum uric acid during the KC1 
period. 
KC1 administration. A mild decrement was also observed in one of the con- 
trol subjects, but no real change occurred in the other. In  general, these 
decreases in serum urate were accompanied by rises in urinary uric acid 
excretion. Utilizing the “student’s t-test,” the changes in serum uric acid 
were statistically significant ( p  < 0.02) while those of the urinary uric acid 
were not ( p  > 0.1)-with the exception of C. W., and in his case the incre- 
ment in uric acid excretion was significant (p  < O.Ol) ,  whereas the serum 
change was not ( p  > 0.1). The rise in uric acid excretion in subject F. B. 
was very small, particularly when viewed in light of the high basal excre- 
tion rate and the major decline in serum uric acid produced by KC1 (fig. 1). 
As illustrated in fig. 2, subject L. A. experienced a drop in serum uric acid 
of over 1 mg. per cent during the first 24 hours of KC1 administration, al- 
though there was no uricosuria during this period, and it was only during 
the second and third days of KC1 therapy that uric acid excretion increased. 
In patient J. M. the marked decrease of serum uric acid during KC1 adminis- 
tration was paralleled by mild uricosuria, but the subsequent rise to pretreat- 
ment blood levels occurred in the absence of any accompanying urate re- 
tention (fig. 3 ) .  C. W. clearly developed uricosuria during the first day of 
KCl administration which persisted throughout the treatment period, but 
the change in serum uric acid in his case was small (fig. 4 ) .  The two 
nonthiazide-treated subjects responded in a manner very similar to C. W.- 
i.e., the changes in serum uric acid were minimal, while uricosuria was 
apparent (fig. 5). 
Thus, although KC1 produced a reduction in serum uric acid, and an in- 
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Fig. 2.-Daily variations in serum uric acid and urate excretion were observed 
in subject L. A. during control and various treatment periods. Prior to, and during 
this study, she was taking chlorothiazide 1.0 Gm. per day. Note that with KCl 
administration the serum uric acid fell over 1.0 mg. per cent during the first day 
of therapy, associated with little change in urate excretion. 
PATIENT J.M. CHLOROTHIAZIDE 2000 m q l D  
SERUM URIC ACID 6.0 
mq. % 5.0 
4.0 
URINARY URIC ACID 400 
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Fig. 3.--Daily variations in serum uric acid and urate excretion in subject 
J. M., who received 2.0 Gm. per day of chlorothiazide prior to and during this 
study. Note that following KC1 administration the serum urate concentration rose 
to its pretreatment level, unassociated with a decrease in iirate excretion below 
baseline values. 
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Fig. 4.-Daily variation in serum uric acid and urate excretion in patient C. W. 
Note that KC1 administration produced a definite uricosuria, but only variable 
changes in serum uric acid. 
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Fig. 5.-Daily variations in serum uric acid, urine urate, urate clearance: 
creatinine clearance ratio, and urine volume, during control and treatment periods 
with NH4C1 and KCI. This subject (R. S.) was not taking chlorothiazide. 
creased urinary urate excretion, these two phenomena did not parallel each 
other, and in some cases definitely discordant changes were observed. 
Mild diuresis occurred during KC1 administration in all subjects except 
L. A. This was most prominent in C. W. and the two nonthiazide-treated 
subjects. These latter two individuals excreted approximately 70 per cent of 
the potassium load administered, while thiazide-treated patients L. A. and 
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Serum Potassium S e m  Bicarbonate 
.e-KCl K C 1  Change Pre-KC1 K C 1  Change 
( w . 1 1 . )  ml.11) 
Table S.--Effect of Potassium Chloride (160 mEq./d.) on Serum Potassium, 
Bicarbonate, Uric Acid, Blood p H ,  and Urinary Potassium (Excretion)* 
Venous Blood pH 
Re-KC1 K C 1  Change 
Urlc Acid (mg.dp) 
SubJect Re-KS1 KC1 Change 
3.50 4,7911.29 
2.37 2.05 +0.48 
3.50 3.75t3.25 
4.01 3.91 -3.10 
L.A.t 6.96 4.85 -2.11 
F.B.1 7.33 5.30 -2.03 
J.M.t  6.05 4.30 -1.75 
c.u.+ 5.28 4.60 -3.68 
26.3 28.2 t1 .9  7.35 7.35 0.0 
3 . 6  33.6 +1.0 7.42 7.44+0.02 
2.9 2.6 -0.3 7.41 7.38-0.03 
29.4 26.2 -3.2 7.37 7.k2 +0.05 
N.W. 5.55 5.50 -0.05 
R.S. 6.69 5.95 -0.65 
5.03 4.79 -0.24 30.7 29.8 -0.9 1 7.38 7.37 -0.01 
4.68 4.38 -0.30 30.3 20.6 -1.7 7.30 7.U t 0 . M  
urine Potassium 
're-KC1 K C 1  Chaw 
( m ~ d 2 4 ' )  
52 131 179 
52 125 +73 
7 2 - -  
74 180 +lo6 
69 184 + l l 5  
58 183 +I25 
*Serum electrolyte and uric acid concentrations before KCI administration ( 160 mEq./ 
day) are compared to those at  the end of the treatment period. The average urinary 
potassium for 3 days prior to KC1 is compared to the mean of all daily excretions 
throughout the treatment period. 
f Thiazide treated. 
F. B. excreted less than 45 per cent. Subject C. W., who had the least change 
in serum uric acid in the thiazide group, excreted nearly 60 per cent of the 
administered potassium. 
Serum potassium concentration dropped slightly in subjects M. W. and 
R. S. (nonthaizide-treated) and was essentially unchanged in subject C. W. 
In subjects J. M. and F. B. the serum potassium rose slightly but remained 
at subnormal limits; in subject L. A. it promptly rose to normal range. Se- 
rum pH and bicarbonate were unchanged by KC1 therapy (table 2).  
Subject L. A. was also given treatment periods of spironolactone, potas- 
sium gluconate, and sodium chloride. Spironolactone elevated the serum po- 
tassium concentration to that produced by KCl, but caused little change in 
serum or urine uric acid (fig. 6) .  Potassium gluconate produced a prompt rise 
in serum potassium concentration and a modest decline in serum uric acid, 
while having no effect on urinary uric acid. Sodium chloride also produced 
a fall in serum uric acid without altering urinary urate excretion. 
Efec t  of NH,C1 
The mean serum uric acid concentration decreased significantly ( p  < 0.05) 
in every subject during NH4C1 administration (table 3 ) .  In those receiving 
chlorothiazide this response was generally less than that produced by KCI, 
while the reverse was true in those subjects not taking the diuretic. Urinary 
uric acid excretion either decreased or remained unchanged in every case 
except one (J. M.). Serum bicarbonate concentration and pH were lower 
at the end of this treatment period in each instance (table 4). Serum sodium 
and potassium levels were altered very little by NH4C1 administration, al- 
though there was a tendency to increased urinary excretion of these electro- 
lytes. Urine volume was also substantially increased during this therapy pe- 
riod in all subjects, but most prominently in F. B. and J. M. 
DISCUSSION 
These data reveal that KC1 lowers serum uric acid in thiazide-treated 
individuals, while having little influence on subjects not receiving thiazides. 
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Fig. 6.-Daily variations in serum uric acid, bicarbonate, and potassium, and 
urinary excretion of sodium and potassium ions, in patient L. A., induced by 
various treatment regimens. Note the lack of correlation between serum potassium 
and uric acid concentrations. 
This effect is apparently not due to increased urinary excretion of uric acid 
alone, since it can appear in the absence of uricosuria and can subside with- 
out subsequent urate retention. KC1 also has a mild uricosuric effect, which 
is of similar magnitude in normal subjects and in those receiving chlorothia- 
zide. NH4C1, on the other hand, decreases serum uric acid in subjects with 
or without thiazide therapy while at the same time tending to decrease urate 
excretion. 
The ability of KCl to correct thiazide hyperuricemia cannot be attributed 
to its effect on serum potassium concentration, because equivalent elevation 
of serum potassium produced by spironolactone did not influence the serum 
uric acid level. Also, impressive decrements of serum uric acid occurred 
during KC1 administration even when this treatment produced relatively 
minor rises of serum potassium, and rises not necessarily to the normal 
range. 
We had suspected that the serum uric acid lowering effect of KCl in 
thiazide-treated subjects might by related to its reported4 ability to correct 
extracellular alkalosis in such individuals. It was for this reason that NH4C1 
was administered and measurements of blood pH and bicarbonate were ob- 
tained throughout the study. It was found that NH4C1, in a dose which in- 
creased blood acidity, did exert a definite hypouricemic effect; however, KC1 
produced no significant alterations in blood pH or bicarbonate content dur- 
ing treatment periods that resulted in substantial decreases in serum uric 
acid. In fact, the response to KCl did not correlate with changes in the con- 
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S e m  Uric  A c i d  (w, $) S e m  Bicarbonate (medl . )  
Subject Pre-NH4Cl NH4Cl Change Pre-NH4cl NH4c1 Chawe - 
L.A. '7.50 5.45 -2.05 25.9 14.4 -11.5 
F.B. 8.06 7.15 -0.91 32.3 25.0 -7.3 
J.M. 5.43 4.65 -0.78 35.4 28.1 -7.3 
C.W. 6.23 .5.25 - 0 . 9  27.1 23.3 -6.8 - 
M.W.  6.40 5.95 -0.45 30.7 25.4 -5.3 
R . S .  6.47 5.35 -1.12 32.3 24.8 -7.5 
b 
Table S.-Eflect of Ammonium Chloride (12 Gm. /d . )  on Serum 
and Urinary Uric Acid" 
Serm u r i c  ac id  (w.8) 
(Erpressed a8 p r  cent) 
F.B.t 8.06 7.15 -0.91 5.60 5.90 t0.30 
J.M.t 5.20 6.05 
3.87 3.54 -0.33 
Venous BlOCd pH 
Pre-WqCl m4c1 Change 
7.31 7.15 -0.16 
7.42 7.35 -0.07 
7.39 7.33 -0.06 
7.41 7.39 -0.m 
7.39 7.31 -0.08 
7.36 7.30 -0.06 
-0.37 o.p I 6.40 5.95 -0.45 773 683 -90 1 ;:: 4.90 6.47 5.35 -1.Z 833 770 -63 5.43 
"Mean of serum uric acid concentrations for 2 or 3 days prior to NH,C1 (12.0 Gm./ 
day) is compared to the mean of the last 2 days of the treatment period. The mean 
of values of urine uric acid and the clearance ratio for 3 days prior to NH,C1 is com- 
pared to the mean of all determinations during the treatment period. 
1Thiazide treated. 
centration oi any of the measured serum or urinary factors except the per 
cent excretion of the administered potassium load. Those subjects who 
showed the greatest hypouricemic response to KCl excreted a smaller pro- 
portion of the potassium load than those who had a lesser response. This 
suggests that the hypouricemic effect of KCl is related to its ability to cor- 
rect a potassium deficiency, and as it does not coincide with changes in se- 
rum potassium concentration, it must be assumed that the deficit is intracellu- 
lar . 
The mechanism of the rmal effect of KCl is not completely apparent from 
our data. Increased urine flow will tend to decrease uric acid reabsorption5r6 
and perhaps some of the urine urate changes produced by KCI are related to 
this phenomenon, since diuresis was observed in almost all subjects during 
KC1 administration. However, in at least one thiazide-treated subject, uri- 
cosuria was observed in the absence of any increase in urine volume. Renal 
excretion of weak acids may also be favored by increased urine pH,?3 and 
thr wine may become more alkaline during potassium l ~ a d i n g . ~  However, 
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in dogs5 and in manlo it has been demonstrated that uric acid excretion is 
relatively uninfluenced by urine pH. Furthermore, in some of our studies 
uricosuria was observed during KCI administration without any change in 
urine pH. If tubular secretion of uric acid were modified by the concentration 
of potassium and/or hydrogen ions within renal tubular cells, KC1 therapy 
might alter the intracellular concentration of these ions and thus produce 
the observed effect on uric acid excretion. 
Blood uric acid concentration is determined primarily by the balance be- 
tween the rates of its production and renal excretion. Other factors which 
may, at least theoretically, influence it are the rate of gastrointestinal excre- 
tion and changes in distribution of urate among body compartments. Our 
data indicate that the decrease in serum uric acid produced by NH4C1 and 
by KCl in thiazide-treated individuals is not due primarily to increased uri- 
nary excretion. Rather, the finding of a tendency toward a decrease in renal 
urate excretion with NH4C1 suggests that administration of this substance 
may inhibit uric acid production, KCl, on the other hand, usually increases 
urinary uric acid content, and so it is difficult to accept that its effect is due 
to impairment of urate production. The apparent correlation between the 
hypouricemic effect of KC1 and repletion of an intracellular potassium deficit 
suggests another possible mechanism, which also could explain the response 
to NH4Cl, redistribution of uric acid. This hypothesis, however, must be 
based on two assumptions: ( a )  that uric acid movement across cell mem- 
branes is determined somewhat by the H30+ gradient across these mem- 
branes and (b )  that cells are potassium depleted and relatively acidotic in 
certain thiazide-treated subjects. Neither assumption is unreasonable. Uric 
acid is a weak acid with a pK, of 5.75 and therefore theoreticallyll its dis- 
tribution among body compartments may be influenced by the phenomenon 
of “non-ionic diffusion.” This phenomenon follows from the fact that biologi- 
cal membranes may be more permeable to the un-ionized than the ionized 
form of weak acids and bases and may allow concentration gradients of these 
substances to develop if there is an initial difference in hydrogen-ion con- 
centrations between the two sides. In fact, Lassen12 has demonstrated that 
uric acid is transported into human erythrocytes more rapidly as extracellu- 
lar pH is decreased and has presented evidence to support his suggestion that 
this is due to non-ionic diffusion. 
It is undisputed that thiazide therapy produces extracellular alkalosis and 
at least a transient period of potassium loss. Potassium depletion induced 
by other means results in acidosis of intracellular fluid.13 It is therefore pos- 
sible that intracellular pH may be depressed in thiazide-treated individuals, 
although this has yet to be measured. 
If uric acid is subject to non-ionic diffusion, and if some thiazide-treated 
subjects are potassium depleted and have an acidotic intracellular space, the 
following interpretation of our data may be rendered: (1) KC1 administration 
lowers blood uric acid in those thiazide-treated subjects who are potassium 
depleted, because it tends to correct this deficiency, thereby causing an 
elevation of intracellular pH resulting in uric acid movement into cells from 
extracellular fluid; (2)  NH4C1 administration lowers serum uric acid in all 
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subjects because it produces extracellular acidosis while having little effect 
on intracellular pH, thereby inducing a movement of uric acid into the cells, 
then relatively more alkaline than the extracellular fluid. 
The failure of blood uric acid to fall as much during administration of an 
equimolar amount of potassium gluconate as it did with KCI does not neces- 
sarily confound the hypothesis that cellular potassium repletion is central 
to the effect of KCl, since, as has been recently emphasized by Kassirer et 
al.,14 the ability of potassium salts to correct potassium deficiency depends 
heavily on the concomitant administration of chloride ion. Similarly, the re- 
sponse to sodium chloride, may be related to the provision of large amounts 
of chloride ion which might facilitate the retention of the ample dietary 
source of potassium in our patients. 
If these assumptions are correct, they also provide a clue to one of the 
mechanisms of production of hyperuricemia by thiazides, which is still the 
subject of debate.l5>l6 One effect of thiazide therapy on urate in the body 
may be a redistribution from the intracellular to the extracellular space, 
secondary to the development of extracellular alkalosis, with or without an 
associated intracellular acidosis. The existence of such a mechanism could 
explain the fact that serum uric acid concentration may rise during thiazide 
therapy while there is no decrease in urinary uric acid e ~ c r e t i 0 n . l ~ ~ ~ ~  
Direct measurements of changes in erythrocyte urate content, fecal uric 
acid excretion, or rate of synthesis of uric acid were not carried out in this 
study. Therefore, the possibilities that large doses of KC1 and NH4CI may 
either decrease the production or increase the nonrenal excretion of uric acid 
have not been excluded by our findings. A purely renal effect, however, has 
been excluded. Further studies of the mechanism of the influence of electro- 
lytes on uric acid metabolism are in order. 
SUMMARY 
The effects on serum and urine uric acid of KCl and NH,Cl administration 
in four chlorothiazide-treated and two control subjects were studied. Serum 
uric acid decreased in three of the four thiazide-treated patients following 
KC1 therapy but not in the control subjects. Potassium chloride also pro- 
duced a moderate uricosuria, but this effect could not be directly linked 
with the changes in serum uric acid. Ammonium chloride administration re- 
sulted in a fall in serum urate in all subjects, with minimal effects on urate 
excretion. It is suggested that these changes could be due to shifts in uric 
acid between the intracellular and extracellular spaces." 
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